In March 2024, resmetirom (MGL-3196), a liver-directed selective thyroid hormone receptor beta (THR-β) agonist, received accelerated approval in the United States for the treatment of adults with MASH and stage 2 or 3 fibrosis and is to date the only drug approved by the Food and Drug Administration for a subset of MASLD [77]. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.